Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission announced the results of the 2023 national clinical laboratory external quality assessment for "bioinformatics analysis of high-throughput sequencing detection of tumor somatic mutations." Tianjin Baikang Hexin Medical Laboratory, the independent clinical trial execution window under ProteinT, successfully passed this external quality assessment with full marks.
External Quality Assessment Statistical Results
The national external quality assessment program for bioinformatics of high-throughput sequencing detection of tumor somatic mutations is an important means of ensuring the detection quality of clinical laboratories. This external quality assessment program can determine the bioinformatics analysis capabilities of participating laboratories, identify common problems as well as special problems in certain laboratories, and promote the improvement of laboratory bioinformatics analysis levels.
With the advent of the precision treatment era, genetic testing has become an indispensable part of the tumor diagnosis and treatment process. Ensuring the accuracy and reliability of genetic testing data processing and interpretation and analysis is the only way to provide effective guidance for subsequent precision tumor treatment. ProteinT has always adhered to high standards and strict requirements to provide high-quality clinical testing services. In this external quality assessment, the reported analysis results for mutation types such as SNV, InDel, CNV, and SV were completely consistent with expectations, all passing with full marks. This fully demonstrates our company's professional analytical capabilities and powerfully proves the team's solid technical strength. In the future, ProteinT will, as always, meticulously build a standardized and normalized quality control system, continuously improve laboratory technical service levels, and continue to provide physicians and patients with high-quality products and professional services!
About Tianjin Baikang Hexin Medical Laboratory
Tianjin Baikang Hexin Medical Laboratory is the independent clinical trial execution window under ProteinT. It is a national high-tech enterprise and a for-profit medical institution approved by the Health Commission, and is equipped with an Illumina NextSeq 500 sequencing system, Thermo Fisher Q-Exactive+/HF, AB SCIEX 4500 mass spectrometry systems, and Bruker Avance III IVDr nuclear magnetic resonance spectrometer detection platforms, with a total value of more than 90 million yuan. It has cumulatively served more than 100 tertiary hospitals and research institutes, with a sample volume of more than 100,000 cases.
About External Quality Assessment
External quality assessment (EQA), also known as proficiency testing, is an internationally recognized important component of comprehensive quality management of clinical laboratories. It is an important tool for health administrative departments and hospital administrators to supervise laboratory quality, and plays a very important positive role in ensuring and improving clinical testing quality and advancing the standardization of clinical testing.
